Prostate Cancer Foundation

donate ribbon

Donate Now    FAQs   Contact Us   Español   twitter   facebook

Navigation

Research News

Zytiga is Most Used First-Line Treatment for Stage IV Prostate Cancer

April 25, 2013 -- Market data released this week shows the new drug’s share of the first-line prostate cancer market has steadily increased to 30 percent since its launch in 2011. The development of this novel new treatment was supported by PCF-funded research.

PCF funded both early science for the development of Zytiga and clinical trials that helped move this promising new drug to patients. Prior to the increased use of Zytiga to treat patients with advanced Stage IV disease, chemotherapy was used to treat three-fourths of first-line patients. Within a month of the FDA’s expanded usage ruling, use of Zytiga rose to 43 percent in first-line therapy for advanced prostate cancer.

Read the ClinicaSpace article

Read more on Zytiga on pcf.org

Back to Research and Therapeutics

Back to All Research News

Print | Bookmark and Share

2000 Programs Worldwide

Progress Reports

prostate cancer guides and books

prostate cancer clinical trials

patient support

athletes for a cure